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Abstract—High drug loading (DL) carrier is an effective way to 
cure the cancerous cells. High drug loading is also one of the key 
issues in the drug delivery research, especially the colonic drug 
delivery system by oral administration. The times of drug intake 
could be remarkably reduced if high drug loading carriers are 
administered. At the same time, the related formulation materials 
could be effectively utilized. One major obstacle with the 
preparation of this system is the difficulty to encapsulate the 
hydrophilic drug into hydrophobic encapsulation polymer. A 
design of high drug loading delivery system with biodegradable, 
biocompatible materials and optimization of the fabrication 
process is a potential solution to solve the problem. So in this 
research, 5-Fluorouracil (5-FU) loaded Poly (lactide-co-glycolide) 
(PLGA) nanoparticles were prepared by double emulsion and 
solvent evaporation method. Several fabrication parameters 
including theoretical drug loading, volume ratio of outer water 
phase to the first emulsion, pH value of outer aqueous phase and 
emulsifier PVA concentration were optimized to get a high drug 
loading nanoparticles.  
The result shows that with the increase of theoretical drug 
loading, the actual drug loading increased gradually. When 
adjusted the pH value of outer aqueous phase to the isoelectric 
point (8.02) of 5-Fluorouracil, the drug loading exhibited a higher 
one compared to other pH value solution. Relative higher volume 
ratio of outer water phase to the first emulsion was also beneficial 
for the enhancement of drug loading.  But the nanoparticles size 
increased simultaneously due to the lower shearing force. When 
increased the PVA concentration, the drug loading showed an 
increase first and following a drop.   
Keywords-5-Fluorouracil (5-FU); PLGA; optimization; 
nanoparticles 
I.  INTRODUCTION 
Colorectal cancer (CRC) is the second cancer related death 
after lung cancer [1]. And Australia has one of the highest 
incidence rates of colorectal cancer in the world. Every year, 
lots of people are diagnosed with or die of this disease. The 
cancerous cells usually begin from non-cancerous cells called 
polyps, but from time to time, it becomes cancerous cells.  
In recent years, the chemotherapy is more and more 
popular, as the traditional treatments like the surgery and 
radiation therapy hurt the patients a lot both in mental and 
physical. The chemotherapy is convenient to be administered 
and painless to the patients. Among the therapeutic drugs 
which have been put into practical use, 5-Fluorouracil (5-FU) is 
one of the most potent and popular ones. Since its introduction 
in 1950s, 5-FU still remains the only effective 
chemotherapeutic agent for the treatment of colorectal cancer 
(CRC) [2]. And using some biodegradable and biocompatible 
polymer like Poly (lactide-co-glycolide) (PLGA) to 
encapsulate the 5-FU into the nanoparticles could diminish the 
side-effect of 5-FU, such as short half life time and rapid 
plasma clearance. Also such a design to form drug delivery 
carrier could control the drug release by the degradation and 
erosion of PLGA. 
The drug loading is one of the key issues in the process of 
such an encapsulation. The times of drug intake could be 
minimized if high drug loading carriers are administered. 5-FU 
is a hydrophilic drug, while the PLGA is a hydrophobic 
polymer. So this kind of encapsulation is not that easy. People 
have been using variety of methods to improve the drug 
loading for the drug delivery carrier. McCarron and co-worker 
substituted the 1-alkylcarbonyloxymethyl, prodrug of 5-FU, for 
the 5-FU [3], which results in the drug loading from 3.68% to 
47.23%. Leo adjusted the pH value of external aqueous phase 
to isoelectric point of the drugs [4]. The result shows an 
obviously high protein encapsulation. Bodmeier et al found that 
the less hydrophilic organic solvent in the oil phase prevented 
the encapsulated hydrophilic drugs from releasing to the outer 
water phase [5].  
In this research, different processing parameters including 
theoretical drug loading, pH value of outer aqueous phase, 
volume ratio of outer water phase to the first emulsion and 
PVA concentration were optimized for the poly (lactide-co-
glycolide) (PLGA) nanoparticles of 5-FU.  
II. MATERIALS AND METHODS 
A. Materials 
PLGA-COOH 50/50 with an average molecular weight of 
40k was purchased from Ji’nan Jidai Biological Co. Ltd 
(Shandong, China). The surfactant used in the emulsification 
process was poly (vinyl alcohol) (PVA) with 86.7%-88.7% 
hydrolysis degree and molecular mass 31k (Sigma Chemical 
CO, USA). All the chemicals used were analytical grade and 
used without further purification.  
Lingxue.kong@deakin.edu.au
                                                                                                                                          1687
B. Preparation of PLGA nanoparticles 
 The PLGA nanoparticles loaded with 5-FU were prepared 
by a modified W1/O/W2 multiple emulsion and solvent 
evaporation technique (Figure 1) as per previous published 
paper [6]. Briefly, 100 mg of PLGA was dissolved in 6 ml 
methylene chloride (DCM). 5-FU was dissolved into a water 
solution which was adjusted concentration to certain value. Into 
the organic phase (O), certain amount of aqueous drug solution 
(W1) was emulsified using probe sonicator for 2 minutes with a 
30% of amplitude to form W1/O emulsion. The primary 
emulsion was injected into an aqueous phase containing Poly 
(vinyl alcohol) (PVA) (external phase, W2) and sonicated for 1 
minutes. The resulting W1/O/W2 emulsion was stirred with a 
magnetic stirrer for 5 hours to allow the solvent evaporation 
and particle hardening. The nanoparticles were then separated 
by ultra-centrifugation at 12k rpm for 20 minutes and washed 
with distilled water for three times, in order to remove the 5-FU 
on the surface of particles and the excess of surfactant. The 
washing solution was eliminated by a further centrifugation. 
The solvent evaporation can also be conducted by rotary 
evaporator at a reduced pressure. Finally, the nanoparticles 
were collected from a freeze-drier and preserved in a desiccator 
until the time of evaluation. 
C. Drug loading(DL) and encapsulation efficiency(EE) of 
PLGA nanoparticles 
To determine the 5-FU amount entrapped in the PLGA 
nanoparticles, indirect method was carried out to test the 
content of the drug in the nanoparticles by measuring the drugs 
that were not encapsulated. The prepared nanoparticle solution 
was centrifuged at 12k rpm for 15 minutes. Then the 
supernatant was collected and tested by ultraviolet-visible (UV) 
spectrometer at a wavelength of 265 nm.  The DL and EE be 
calculated in the following equations: 
                      Drug loading (DL)/% = (A-B)/C*100             (1) 
        Encapsulation efficiency (EE)/% = (A-B)/A*100       (2) 
A: total drugs  
B: drug in supernatant 
C: weight of nanoparticles 
III. RESULTS AND DISCUSSION 
A. Effect of theoretical drug loading of 5-FU 
In order to encapsulate large amount of drugs into the 
nanoparticles and figure out how the theoretical drug loading 
affects the actual drug loading of the nanoparticles, four 
theoretical drug loading amounts 5%, 10%, 15% and 20% 
(w/w) were selected. From the table I, as the increase of 
theoretical drug loading, actual drug loading ranges from 2.4% 
to 6.8%. However, the corresponding drug encapsulation 
efficiency decreases from 27.58% to 17.13%. The reason for 
that is the stability of first emulsion was reduced when initial 
drug feeding increased. So if small amount of drugs were 
feeded in the fabrication process, the drug loading would be 
higher. But in this case, the encapsulation efficiency is a little 
low. The patients who take the drugs have to increase the times 
and frequency of drug administration, in order to keep enough 
drug concentration in the body. If high amount of drugs are 
feeded in the preparation, lot of drugs could not be 
encapsulated in and result in the loss of expensive drugs. So the 
compromise scheme should be retrieved. That is to get a 
relative high drug loading and decrease the manufacturing cost. 
10% of the initial drug feeding seems to be the optimal 
formulation, as it keeps a balance of relative high drug loading 
and encapsulation efficiency. So in the following preparation, 
the 10% theoretical drug loading was used as the starting 
parameter.  
TABLE I.  EFFECT OF THEORETICAL DRUG LOADING ON THE PROPERTY 
OF THE PRODUCTS 
  a. Theoretical drug loading 
B. Volume ratio of the outer water phase to first emulsion on 
the drug loading 
In the W1/O/W2 fabrication process, first emulsion is the 
dispersing phase; while the outer water phase is the continuous 
phase. For the double emulsion preparation method, the outer 
water phase is used for hardening the nanoparticles and 
promoting the organic solvent to be evaporated. In this 
research, we used the DCM as the organic solvent, as it has the 
properties of polarity, less toxicity and low boiling point. And  
 
Figure 1.  Volume ratio of the outer water phase to first emulsion on drug 
loading and encapsulation efficiency 
its solubility in water is 13 g/L at 20oC [7]. With the increase of 
this volume ratio, the actual drug loading increased and the 
surface of the nanoparticles prepared at a high volume ratio 
was much smoother compared to that prepared at a low ratio 
one. The reason is as follows, after the formation of the double 
emulsion, it has to be agitated for several hours in order to 
eliminate the organic solvent. If there is a small amount of 
outer water phase, the DCM could not be easily diffused and 
released out and then be dissolved into water. This results in 
TRLa Size (nm) PDI (poly-dispersity) DL (%) EE (%) 
5% 189.2 0.190 2.4 27.58 
10% 205.4 0.153 4.9 25.80 
15% 214.5 0.124 6.3 19.20 
20% 233.6 0.165 6.8 17.13 
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particles forming a longer time, which the drugs in the first 
emulsion could travel to outer water phase due to its 
hydrophilic property. If the volume of outer water phase is 
higher, that could speed up the solidification time at high 
volume ratio of the outer water phase to first emulsion. At the 
same time, we found that the nanoparticles prepared by the 
high volume ratio have larger size than that of the low volume 
ratio one. The probe sonicator was performed when the first 
emulsion was emulsified into the second emulsion. The large 
outer water phase may decrease the sonication efficiency. So 
the increase in the particle size was probably attributed to 
reduction of the shearing force during the formation of second 
emulsion and the homogenization process. 
TABLE II.  EFFECT OF VOLUME RATIO ON THE PROPERTY OF THE 
PRODUCT 
C. pH value of outer aqueous phase 
Normally the solubility of drug is pH dependent. And when 
a drug is dissolved into a solution whose pH adjusts to the 
drug’s isoelectric point, fewer drugs would be dissolved into 
the solution [4]. For the 5-FU, the isoelectric point is 8.02. In 
order to compare the effect of pH in the outer aqueous phase, 
three different pH values 5.0, 8.02 and 10.0 were selected. 
From the figure 2, we could clearly see that the products 
prepared by 8.02 pH value of outer water phase exhibit a high 
drug loading. During the process of nano-fabrication, when we 
got the first emulsion and kept further emulsifying in the outer 
water phase, the drugs in the first emulsion could be easily 
released out due to its appetency to aqueous phase. By altering 
the outer aqueous phase pH value to the isoelectric point of   
 
 
 
 
 
 
 
 
 
 
Figure 2.  Influence of pH value on drug loading and encapsulation efficiency 
drugs could obviously reduce the drug loss, as the drugs have 
the minimum soluble in that pH value solution.  
D. PVA concentration 
The PVA located between the oil phase and the water phase 
to stabilize the formed nano-emulsion and prevent the 
aggregation. The nanoparticles were formed with the help of 
PVA to stabilize the emulsion solvent and droplets formation. 
Different PVA concentrations were used in the sonication and 
homogenization process, in order to study the external aqueous 
phase on the nanoparticles properties. 0.2%, 0.6% and 1.2% 
(w/v) concentration PVA were selected to do the experiments.   
The prepared nanoparticles with higher concentration PVA 
exhibited a slight higher particle size than the one with lower 
concentration. The larger particle size of nanoparicles with 
higher surfactant is probably due to the adsorption of surfactant 
to the particle surface. Although repeated washings were 
conducted, some of the adsorbed PVA were not washed away. 
TABLE III.   INFLUENCE OF PVA CONCENTRATION ON PARTICLE SIZE AND 
DRUG LOADING 
concentrationa Particle size (nm) 
PDI (poly-
dispersity) DL (%) EE (%) 
0.2% 185 0.163 5.2 22.3 
0.6% 204 0.110 5.6 25.8 
1.2% 237 0.145 4.2 19.6 
a. PVA concentration (w/v) 
From the table III, when the PVA concentration increases 
to 1.2% (w/v), the drug loading dropped dramatically. This is 
probably ascribed to the residue PVA on the particle surface. 
Based on the equation 1, if the residue existed in the final 
product, the addition of the PVA weight was ignored, which 
result in the lower calculation of the drug loading.  
CONCLUSIONS 
In this research, 5-FU loaded PLGA nanoparticles were 
prepeared by the double emulsion and solvent evaporation 
method. Different processing parameters were optimized to 
get a high drug loading carrier. Results indicated that the 
particles prepared by high theoretical drug loading got a high 
actual drug loading, while the corresponding encapsulation 
efficiency was a little low. Adjusting pH of the outer water 
phase to the isoelectric point of the drug and high volume ratio 
of outer water phase to first emulsion could enhance the drug 
loading. Proper amount of PVA concentration was beneficial 
to increase the drug loading.  
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